我们现在有固定的给药剂量、产生一致且可预测的抗凝反应且无需常规监测的新口服抗凝药物。
We now have new oral anticoagulants that can be given in fixed doses, produce a consistent and predictable anticoagulant response and don't require routine coagulation monitoring.
本研究旨在针对触发和非触发人群，当终止口服抗凝药物治疗后，探究如何识别VTE复发的最强预测因子。
We aimed to identify the strongest predictors of VTE recurrence after discontinuation of oral anticoagulant therapy in a population of both provoked and unprovoked patients.
对于伴有主动脉弓活动性血栓的不明原因卒中患者，建议或者口服抗凝，或者服用抗血小板药物(2c级)。
For patients with cryptogenic stroke associated with mobile aortic arch thrombi, we suggest either oral anticoagulation or antiplatelet agents (Grade 2c).
此外，尽管口服抗凝药的实验监测也许并无必要，但还需开发这类药物的解毒剂并对其效果加以检测。
Moreover, although lab monitoring with oral anticoagulant may not be necessary, antidotes of such compounds still need to be developed and tested for their efficacy.
此外，尽管口服抗凝药的实验监测也许并无必要，但还需开发这类药物的解毒剂并对其效果加以检测。
Moreover, although lab monitoring with oral anticoagulant may not be necessary, antidotes of such compounds still need to be developed and tested for their efficacy.
应用推荐